Timothy DeVere Cook - Jul 29, 2022 Form 4 Insider Report for Athenex, Inc. (ATNXQ)

Role
Chief Business and Commercial Officer, Proprietary Drugs
Signature
/s/Steven Adams, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Jul 29, 2022
Transactions value $
$500
Form type
4
Date filed
8/1/2022, 04:24 PM
Previous filing
Jul 21, 2022
Next filing
Aug 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Award $500 +986 +12.12% $0.51* 9.12K Jul 29, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) 70K Jul 29, 2022 Common Stock 70K $17.29 Direct F2
holding ATNXQ Stock Option (Right to Buy) 30K Jul 29, 2022 Common Stock 30K $10.26 Direct F3
holding ATNXQ Stock Option (Right to Buy) 9K Jul 29, 2022 Common Stock 9K $3.56 Direct F4
holding ATNXQ Restricted Stock Units 9K Jul 29, 2022 Common Stock 9K Direct F5, F6
holding ATNXQ Stock Option (Right to Buy) 75K Jul 29, 2022 Common Stock 75K $0.67 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
F2 This option vests in four equal annual installments beginning on August 16, 2019.
F3 This option vests in four equal annual installments beginning on August 27, 2021.
F4 This option vests in four equal annual installments beginning on September 16, 2022.
F5 Each restricted stock unit represents a contingent right to receive one share of stock.
F6 The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F7 This option vests in four equal annual installments beginning on July 20, 2023.

Remarks:

Chief Business and Commercial Officer, Proprietary Drugs